0.75 (2.49%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Neutral
Earnings
Neutral
Earnings
Very Weak
Dividends
Very Weak
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Website
Celldex Therapeutics, Inc.
Telephone
1.908.454.7120
Address
Suite 220, 53 Frontage Road, Perryville III Building, Hampton, NJ 08827
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 18.55 - 35.79
Trade Value (12mth)
US$6,510,667.00
1 week
-3.8%
1 month
-11.97%
YTD
11.63%
1 year
51.13%
All time high
705.60
EPS 3 yr Growth
62.60%
EBITDA Margin
NaN%
Operating Cashflow
-$211m
Free Cash Flow Return
-33.00%
ROIC
-40.50%
Interest Coverage
0.00
Quick Ratio
10.50
Shares Outstanding (Fully Diluted)
67m
HALO Sector
Healthcare
Next Company Report Date
01-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 08 May 26 | |
| 08 May 26 | |
| 08 May 26 | |
| 08 May 26 | |
| 03 April 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -2.92 | -2.45 | -3.9 | | | | ||
EPS (Fully Diluted) | $ | | | | | -2.92 | -2.45 | -3.9 | | | | ||
Growth | % | | | | | -21.9 | 16 | -58.9 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
